Baqsimi

Active Ingredient(s): Glucagon
FDA Approved: * July 24, 2019
Pharm Company: * ELI LILLY AND CO
Category: Hypoglycemia

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Baqsimi Overview

1BH0, 1NAU, 2G49, 2M5P, 2M5Q,%%s4ZGM, 4APD, 3IOL, 1D0R,%%s2L64, 2L63IdentifiersAliasesGCG, GLP1, glucagon, GRPP, GLP-1, GLP2External IDsOMIM: 138030 HomoloGene: 136497 GeneCards: GCG Gene location (Human)Chr.Chromosome 2 (human)[1]Band2q24.2Start162,142,882 bp[1]End162,152,404 bp[1]RNA expression patternBgeeTop expressed in islet of Langerhans duodenum pancreas Body of pancreas rectum sigmoid colon organ system colonMore reference expression da...

Read more Baqsimi Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Glucagon

Recent Baqsimi Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Glucagon
  • Injection: 0.5mg, 10mg/vial, 1mg, 1mg/vial
  • Powder: 1mg/vial, 3mg
  • Solution: 0.5mg/0.1ml (0.5mg/0.1ml), 1mg/0.2ml (1mg/0.2ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Baqsimi: (1 result)

Sorted by National Drug Code
  • 0002-6145 Baqsimi 3 mg Nasal Powder by Eli Lilly and Company

Other drugs which contain Glucagon or a similar ingredient: (5 results)